The Jiang Lab is currently investigating 
novel strategies to improve cancer immunotherapies at Henry Ford Health + Michigan State University. Here we target dendritic cells (DC) and their cross-priming behavior on tumor antigen-specific CD8 T cells towards this goal.

Dendritic cell (DC)-mediated cross-priming of CD8 T cells plays a critical role in determining the efficacy of cancer immunotherapies, including Immune Checkpoint Blockade (ICB) and Adaptive Cell transfer (ACT). Using pre-clinical DC vaccine models, our group focuses on understanding how subsets of DCs present tumor antigens to activate tumor antigen-specific CD8 T cells and how these processes are regulated. We aim to capitalize on this new knowledge for DC-mediated cross-priming as a new strategy to improve cancer immunotherapies. Our laboratory continues to grow with our collaborations within the Center, Henry Ford Health, Michigan State University, and numerous investigators worldwide. We are currently investigating the following projects since inception in 2000.